ArticleBMC microbiology2019
Genomic analyses of two novel biofilm-degrading methicillin-resistant Staphylococcus aureus phages.
Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the use of bacteriophages for in vitro biofilm control.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Pooled it
- Biofilm-Forming Methicillin-Resistant Staphylococcus aureus: A Comprehensive Phenotypic and Genotypic Review.Cureus · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Bacteriophages and Endolysins Used in the Biocontrol ofMicroorganisms · 2025Review
- Proteomic analysis reveals phage-driven metabolic shifts and biofilm disruption in methicillin-resistant Staphylococcus aureus (MRSA).World journal of microbiology & biotechnology · 2025Article
- NIR light-driven nanomotor with cascade photodynamic therapy for MRSA biofilm eradication and diabetic wound healing.Theranostics · 2025Article
- Review
- Article
- Biological Characterization and Genomic Analysis of Three NovelInternational journal of molecular sciences · 2024Article
- Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review.European journal of microbiology & immunology · 2024Review
- Genomic characterization, in vitro, and preclinical evaluation of two microencapsulated lytic phages VB_ST_E15 and VB_ST_SPNIS2 against clinical multidrug-resistant Salmonella serovars.Annals of clinical microbiology and antimicrobials · 2024Article
- Emerging roles of bacteriophage-based therapeutics in combating antibiotic resistance.Frontiers in microbiology · 2024Review
- Newly Isolated Virulent Salmophages for Biocontrol of Multidrug-ResistantInternational journal of molecular sciences · 2023Article
- Synergistic action of phages and lytic proteins with antibiotics: a combination strategy to target bacteria and biofilms.BMC microbiology · 2023Article
- Characteristics of a novel temperate bacteriophage against Staphylococcus arlettae (vB_SarS_BM31).International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- Statistical optimization of a podoviral anti-MRSA phage CCASU-L10 generated from an under sampled repository: Chicken rinse.Frontiers in cellular and infection microbiology · 2023Article
- Article
- An Anti-MRSA Phage From Raw Fish Rinse: Stability Evaluation and Production Optimization.Frontiers in cellular and infection microbiology · 2022Article
- How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections.Infection and drug resistance · 2022Review
- Phage Revolution Against Multidrug-Resistant Clinical Pathogens in Southeast Asia.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) biofilm producers represent an important etiological agent of many chronic human infections. Antibiotics and host immune responses are largely ineffective against bacteria within biofilms. Alternative actions and novel antimicrobials should be considered. In this context, the use of phages to destroy MRSA biofilms presents an innovative alternative mechanism.
resultsTwenty-five MRSA biofilm producers were used as substrates to isolate MRSA-specific phages. Despite the difficulties in obtaining an isolate of this phage, two phages (UPMK_1 and UPMK_2) were isolated. Both phages varied in their ability to produce halos around their plaques, host infectivity, one-step growth curves, and electron microscopy features. Furthermore, both phages demonstrated antagonistic infectivity on planktonic cultures. This was validated in an in vitro static biofilm assay (in microtiter-plates), followed by the visualization of the biofilm architecture in situ via confocal laser scanning microscopy before and after phage infection, and further supported by phages genome analysis. The UPMK_1 genome comprised 152,788 bp coding for 155 putative open reading frames (ORFs), and its genome characteristics were between the Myoviridae and Siphoviridae family, though the morphological features confined it more to the Siphoviridae family. The UPMK_2 has 40,955 bp with 62 putative ORFs; morphologically, it presented the features of the Podoviridae though its genome did not show similarity with any of the S. aureus in the Podoviridae family. Both phages possess lytic enzymes that were associated with a high ability to degrade biofilms as shown in the microtiter plate and CLSM analyses.
conclusionsThe present work addressed the possibility of using phages as potential biocontrol agents for biofilm-producing MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.